Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + fluorouracil
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Capecitabine + fluorouracil is a combination of two antimetabolite chemotherapeutic agents used primarily in the treatment of various solid tumors, especially gastrointestinal and breast cancers. Capecitabine is an orally administered prodrug that is enzymatically converted to its active form, fluorouracil (5-FU), within tumor tissues. Fluorouracil acts as a pyrimidine analog, interfering with DNA and RNA synthesis by inhibiting thymidylate synthase and incorporating into RNA, leading to cytotoxicity in rapidly dividing cancer cells. This combination may be used sequentially or concurrently in certain regimens for enhanced efficacy against cancers such as colorectal, gastric, pancreatic, esophageal, and breast cancer[1][4][6][7]. Both drugs are classified as antimetabolites within the broader class of cytotoxic chemotherapy.
- Brand names
- XelodaXitabinCapcibinKapetralPecasetAdrucilEfudixActikerall
- Other names
- 5-fluorouracil5-FU
02
Targets
TS (Thymidylate synthase)
Beyond the preview
Go deeper on capecitabine + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + fluorouracil.